CompletedPhase 1NCT02342574

F901318 Multiple Ascending Dose Study

Studying Aspergillosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
F2G Biotech GmbH
Principal Investigator
Frans van den Berg, MB ChB
Hammersmith Medicines Research
Intervention
F901318(drug)
Enrollment
72 enrolled
Eligibility
18-45 years · MALE
Timeline
20152016

Study locations (1)

Collaborators

Hammersmith Medicines Research

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02342574 on ClinicalTrials.gov

Other trials for Aspergillosis

Additional recruiting or active studies for the same condition.

See all trials for Aspergillosis

← Back to all trials